Accuvest Global Advisors Acquires 10,447 Shares of Pfizer Inc. (PFE)

Accuvest Global Advisors raised its holdings in Pfizer Inc. (NYSE:PFE) by 6,696.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 10,603 shares of the biopharmaceutical company’s stock after acquiring an additional 10,447 shares during the quarter. Accuvest Global Advisors’ holdings in Pfizer were worth $385,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Texas Yale Capital Corp. boosted its stake in Pfizer by 1.5% during the second quarter. Texas Yale Capital Corp. now owns 83,436 shares of the biopharmaceutical company’s stock worth $3,027,000 after acquiring an additional 1,255 shares in the last quarter. Ken Stern & Associates Inc. boosted its stake in Pfizer by 7.2% during the second quarter. Ken Stern & Associates Inc. now owns 18,906 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 1,266 shares in the last quarter. Abbrea Capital LLC boosted its stake in Pfizer by 2.0% during the second quarter. Abbrea Capital LLC now owns 64,420 shares of the biopharmaceutical company’s stock worth $2,337,000 after acquiring an additional 1,274 shares in the last quarter. American Asset Management Inc. boosted its stake in Pfizer by 4.7% during the second quarter. American Asset Management Inc. now owns 28,631 shares of the biopharmaceutical company’s stock worth $1,039,000 after acquiring an additional 1,279 shares in the last quarter. Finally, Private Wealth Advisors Inc. boosted its stake in Pfizer by 6.7% during the second quarter. Private Wealth Advisors Inc. now owns 20,600 shares of the biopharmaceutical company’s stock worth $747,000 after acquiring an additional 1,285 shares in the last quarter. Hedge funds and other institutional investors own 68.96% of the company’s stock.

Several research analysts recently issued reports on PFE shares. JPMorgan Chase & Co. reissued a “buy” rating and set a $42.00 target price on shares of Pfizer in a research note on Wednesday, July 11th. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, July 11th. Credit Suisse Group set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, July 12th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, July 15th. Finally, Jefferies Financial Group set a $39.00 target price on shares of Pfizer and gave the stock a “hold” rating in a research note on Sunday, July 15th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $42.67.

PFE opened at $43.01 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81. The firm has a market cap of $255.56 billion, a price-to-earnings ratio of 16.23, a price-to-earnings-growth ratio of 2.16 and a beta of 0.88.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The firm had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. The business’s revenue was up 1.0% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 3 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.16%. Pfizer’s payout ratio is 51.32%.

In other news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction dated Monday, October 15th. The stock was bought at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the sale, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

WARNING: “Accuvest Global Advisors Acquires 10,447 Shares of Pfizer Inc. (PFE)” was originally posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://theenterpriseleader.com/2018/11/07/accuvest-global-advisors-acquires-10447-shares-of-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply